1
|
Kuentz P, Engel C, Laeng M, Chevarin M, Duffourd Y, Martel J, Piard J, Morice-Picard F, Aubert H, Bessis D, Guerrot AM, Maruani A, Boccara O, Mazereeuw-Hautier J, Ott H, Phan A, Puzenat E, Quelin C, Thauvin-Robinet C, Faivre L, Vabres P. Clinical phenotype of the PIK3R1-related vascular overgrowth syndrome. Br J Dermatol 2024:ljae167. [PMID: 38623710 DOI: 10.1093/bjd/ljae167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 03/25/2024] [Accepted: 04/12/2024] [Indexed: 04/17/2024]
Abstract
Here we report 19 additional mosaic PIK3R1 patients with clinical phenotyping, showing that the PIK3R1 phenotype is indistinguishable from the PIK3CA-related phenotypes, although the MCAP phenotype is consistently absent in PIK3R1 patients. We also report novel PIK3R1 variants. We consider that the meaning of PROS should shift from “PIK3CA-related overgrowth spectrum” to “PI3-kinase-related overgrowth spectrum”.
Collapse
Affiliation(s)
- Paul Kuentz
- Université de Franche-Comté, CHU Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, F-25000 Besançon, France
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
| | - Camille Engel
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- Université de Franche-Comté, CHU Besançon, Centre de Génétique Humaine, F-25000 Besançon, France
| | - Mathieu Laeng
- Université de Franche-Comté, CHU Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, F-25000 Besançon, France
| | - Martin Chevarin
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- CHU Dijon, Unité Fonctionnelle "Innovation diagnostique dans les maladies rares", FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
| | - Yannis Duffourd
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- CHU Dijon, Unité Fonctionnelle "Innovation diagnostique dans les maladies rares", FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
| | - Jéhanne Martel
- CHU Dijon, Centre de référence MAGEC Nord "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
| | - Juliette Piard
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- Université de Franche-Comté, CHU Besançon, Centre de Génétique Humaine, F-25000 Besançon, France
| | - Fanny Morice-Picard
- CHU Bordeaux, Service de Dermatologie, Centre de référence MAGEC Sud "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", F-33000 Bordeaux, France
| | - Helene Aubert
- CHU Nantes, Service de Dermatologie, F-44000 Nantes, France
| | - Didier Bessis
- CHU Montpellier, Service de Dermatologie, F-34000 Montpellier, France
| | - Anne-Marie Guerrot
- CHU Rouen, Service de Génétique, NGP "Centre normand de médecine génomique et de médecine personnalisée", F-76000 Rouen, France
| | - Annabel Maruani
- CHU Tours, Service de Dermatologie, Centre de référence MAGEC Nord "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", F-37000 Tours, France
| | - Olivia Boccara
- CHU Necker-Enfants Malades, Service de Dermatologie, Centre de référence MAGEC Nord "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", F-75000 Paris, France
| | - Juliette Mazereeuw-Hautier
- CHU Toulouse, Service de Dermatologie, Centre de référence MAGEC Sud "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", F-31000 Toulouse, France
| | - Hagen Ott
- Kinder- und Jugendkrankenhaus Auf der Bult, Pädiatrische Dermatologie und Allergologie, Epidermolysis bullosa-Zentrum, D-30000 Hannover, Deutschland
| | - Alice Phan
- HCL-Femme-mère-enfant, Service de Néphrologie-Rhumatologie-Dermatologie, F-69029 Bron, France
| | - Eve Puzenat
- Université de Franche-Comté, CHU Besançon, Service de Dermatologie, F-25000 Besançon, France
| | - Chloe Quelin
- CHU Rennes, Service de génétique clinique, F-35000 Rennes, France
| | - Christel Thauvin-Robinet
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- CHU Dijon, Unité Fonctionnelle "Innovation diagnostique dans les maladies rares", FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
| | - Laurence Faivre
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- CHU Dijon, Centre de Génétique et Centres de référence Anomalies du Développement et Déficience Intellectuelle, FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
| | - Pierre Vabres
- Université de Bourgogne, INSERM UMR1231 GAD "Génétique des Anomalies du Développement", F-21000 Dijon, France
- CHU Dijon, Centre de référence MAGEC Nord "Maladies rares de la peau et des muqueuses d'origine Génétique à Expression Cutanée", FHU-TRANSLAD et Institut GIMI, F-21000 Dijon, France
- Reference centre for rare diseases, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| |
Collapse
|
2
|
Bisdorff-Bresson A, Boccara O. Chronic wounds in superficial vascular malformations of lower and/or upper extremities. J Med Vasc 2024; 49:63-64. [PMID: 38697711 DOI: 10.1016/j.jdmv.2024.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2024]
Affiliation(s)
- A Bisdorff-Bresson
- Department of Neuroradiology, Lariboisière Hospital, 2, rue Ambroise-Paré, 75010 Paris, France.
| | - O Boccara
- Department of Dermatology Necker, Lariboisère Hospital, 49, rue de Sèvres, 75015 Paris, France
| |
Collapse
|
3
|
Fath L, Simon F, Levy R, Boccara O, Couloigner V. Dangers and therapeutic difficulties of intracranial hemangioma in infants: A CARE case report. Eur Ann Otorhinolaryngol Head Neck Dis 2024:S1879-7296(24)00018-8. [PMID: 38395664 DOI: 10.1016/j.anorl.2024.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2024]
Abstract
INTRODUCTION Description of neurological complications induced by intracranial hemangioma in infants and by the initiation of beta-blocker treatment (propranolol). OBSERVATION A 2-month-old infant was referred for grade 5 non-congenital unilateral peripheral facial palsy. Work-up revealed ipsilateral profound hearing loss and two intracranial hemangiomas: one in the ipsilateral internal auditory canal (IAC), the other in the cerebellum opposite the nodule of vermis. Initial treatment with a beta-blocker (propranolol 1mg/kg/day for 1month, then 3mg/kg/day) resulted in disappearance of symptoms and regression of lesions within 8weeks. At 20months after introduction of maintenance therapy (propranolol 3mg/kg/day), two asthma attacks occurred, leading to initiation of fluticasone and continuation of the beta-blocker. Thirty months after discontinuation of treatment, no further progression was noted. DISCUSSION Unilateral facial palsy in an infant suggests a number of diagnoses. MRI revealed IAC hemangioma. The choice of dosage and duration of treatment was based on a review of the literature and a strategy defined in multidisciplinary consultation.
Collapse
Affiliation(s)
- Léa Fath
- Service d'ORL et Chirurgie Cervicofaciale Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France.
| | - François Simon
- Service d'ORL et Chirurgie Cervicofaciale Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Raphaël Levy
- Service de Radiologie Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Olivia Boccara
- Service de Dermatologie Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Vincent Couloigner
- Service d'ORL et Chirurgie Cervicofaciale Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
| |
Collapse
|
4
|
Leducq S, Maruani A, Bodemer C, Biscardi S, Boccara O, Chinazzo MF, Mahé E, Plantin P, Fraitag S, Mazereeuw-Hautier J, Chiaverini C, Lemelle I, Bessis D, Bourrat E, Mallet S, Bonniaud B, Grall-Lerosey M, Martin L, Boralevi F, Piram M. Accurate diagnosis of acute hemorrhagic edema of infancy: a French multicenter observational study. Eur J Pediatr 2023; 182:4133-4141. [PMID: 37432503 DOI: 10.1007/s00431-023-05098-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 06/29/2023] [Accepted: 07/04/2023] [Indexed: 07/12/2023]
Abstract
The purpose of the study is to highlight clinical signs that are either suggestive of or against the diagnosis of AHEI to improve diagnosis and management. The medical records of children under 3 years old diagnosed with AHEI were retrospectively reviewed. Clinical data and photographs were reviewed by three independent experts, and the cases were classified as probable, doubtful, or unclear AHEI. Of the 69 cases of children diagnosed with AHEI included in 22 centers, 40 were classified as probable, 22 as doubtful, and 7 as unclear. The median age of patients with probable AHEI was 11 months [IQR 9-15], and they were in overall good condition (n = 33/40, 82.5%). The morphology of the purpura was targetoid in 75% of cases (n = 30/40) and ecchymotic in 70% of cases (n = 28/40) and affected mostly the legs (n = 39/40, 97%), the arms (n = 34/40, 85%), and the face (n = 33/40, 82.5%). Edema was observed in 95% of cases and affected mostly the hands (n = 36/38, 95%) and feet (n = 28/38, 74%). Pruritus was absent in all patients with probable AHEI and described for 6/21 with doubtful AHEI (29%). AHEI was the original diagnosis in only 24 patients (n = 24/40, 60%). The major differential diagnoses were purpura fulminans and urticaria multiforme. Conclusion: AHEI, which the diagnosis is made on clinical findings, is often misdiagnosed. Purpuric lesions localized on the face/ears, arms/forearms, and thighs/legs with edema of the hands without pruritus in a young child with a good overall condition are highly suggestive of AHEI. What is Known: •Acute hemorrhagic edema of infancy (AHEI) is a cutaneous leukocytoclastic vasculitis affecting children under 3 years old. •Appropriate diagnosis is important to distinguish this benign disease from more serious diseases to avoid investigations and treatments, iatrogenic harm and unnecessary follow-up. What is New: •AHEI is an uncommon disorder often misdiagnosed by pediatricians and dermatologists. •Purpuric lesions localized on the face/ears, arms/forearms, and thighs/legs with edema of the hands without pruritus in an infant with a good overall condition are highly suggestive of AHEI.
Collapse
Affiliation(s)
- Sophie Leducq
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), Unit of Pediatric Dermatology, CHRU Tours, Tours, France.
- Universities of Tours and Nantes, INSERM 1246-SPHERE, , Tours, France.
| | - Annabel Maruani
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), Unit of Pediatric Dermatology, CHRU Tours, Tours, France
- Universities of Tours and Nantes, INSERM 1246-SPHERE, , Tours, France
| | - Christine Bodemer
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Paris University, Necker-Enfants Malades Hospital, Paris Centre University, Imagine Institute, Paris, France
| | | | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Paris University, Necker-Enfants Malades Hospital, Paris Centre University, Imagine Institute, Paris, France
| | | | - Emmanuel Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | | | - Sylvie Fraitag
- Pathology Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | | | | | - Irene Lemelle
- Paediatric Onco-Haematology, Brabois Hospital, University Hospital of Nancy, Vandoeuvre-Lès-Nancy, France
| | - Didier Bessis
- Department of Dermatology, University Hospital of Montpellier, Montpellier, France
| | - Emmanuelle Bourrat
- Department of General Pediatrics, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Stéphanie Mallet
- Department of Dermatology, Hôpital Timone, Aix-Marseille Université, Marseille, France
| | - Bertille Bonniaud
- Department of Dermatology and Genetics of Developmental Anomalies, UMR Inserm 1231, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079, Dijon, France
| | | | | | - Franck Boralevi
- Pediatric Dermatology Unit, Hôpital Pellegrin-Enfants, CHU de Bordeaux, France
| | - Maryam Piram
- Department of Pediatrics, CHU Sainte Justine Research Centre, Sainte Justine University Hospital, University of Montreal, Montreal, QC, Canada
| |
Collapse
|
5
|
Orly J, Bisdorff A, Fraissenon A, Joly A, Boulouis G, Guibaud L, Tavernier E, Mallet S, Marcelin C, Miquel J, Martin L, Droitcourt C, Gusdorf L, Abasq C, Dadban A, Chiaverini C, Vabres P, Herbreteau D, Boccara O, Wassef M, Maruani A. Intramuscular capillary-type hemangioma: Diagnosis, treatment, and outcomes. A French multicentric retrospective study of 66 cases. Eur J Radiol 2023; 165:110962. [PMID: 37423018 DOI: 10.1016/j.ejrad.2023.110962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/02/2023] [Accepted: 07/03/2023] [Indexed: 07/11/2023]
Abstract
PURPOSE Intramuscular capillary-type hemangiomas (ICTHs) are rare entities, belonging to the group of intramuscular "hemangiomas." The diagnosis remains challenging. We aimed to assess the diagnostic criteria, treatments and outcomes of ICTHs. METHODS This retrospective study collected all cases of ICTH followed up in 9 French hospital centers, reviewed by an adjudication expert group. RESULTS Among 133 patients screened, 66 with ICTH were included. The median age of patients at diagnosis was 28.0 years, interquartile range (21.0---36.0). The lesion, mainly presenting as a gradually increasing mass (83.9%), was painless (88.9%) and was located in the head and neck (42.4%). MRI (available in all cases) mainly revealed a well-delineated lesion, isointense to the muscle on T1-weighted images, with enhancement after contrast injection; hyperintense on T2-weighted images; and containing flow voids. Among the 66 cases, 59 exhibited typical ICTH features and 7 shared some imaging features with arteriovenous malformations. These latter were larger than typical ICTHs and more painful and appeared on imaging as less well delimited and more heterogeneous tissue masses, with larger tortuous afferent arteries, earlier draining vein opacification and mild arteriovenous shunting. We propose to name these lesions arteriovenous malformation (AVM)-like ICTH. Pathological reports were similar in typical and AVM-like ICTH, showing capillary proliferation with mainly small-size vessels, negative for GLUT-1 and positive for ERG, AML, CD31 and CD34, with low Ki67 proliferation index (<10%), and adipose tissue. The most frequent treatment for ICTH was complete surgical resection (17/47, 36.2%), preceded in some cases by embolization, which led to complete remission. CONCLUSIONS ICTH can be diagnosed on MRI when it is typical. Biopsy or angiography are required for atypical forms.
Collapse
Affiliation(s)
- Jordan Orly
- CHRU Tours, Department of Dermatology, Unit of Pediatric Dermatology, Tours, France; Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France
| | - Annouk Bisdorff
- Reference Center for Vascular Anomalies FAVA-multi, University Hospital of Lariboisière, Coordinator of the Constitutive Center for Superficial Arteriovenous Malformations in Children and Adults, AP-HP, Department of Neuroradiology, Paris, France
| | - Antoine Fraissenon
- Service d'Imagerie, Consultation Multidisciplinaire des Angiomes, Centre de Compétence National Malformations Vasculaires Superficielles, Hôpital Femme Mère Enfant, Université Claude Bernard Lyon 1, Lyon-Bron, France; Service de Radiologie Mère-Enfant, Hôpital Nord, Saint-Etienne, France; CREATIS, UMR 5220, U1294 Lyon, France
| | - Aline Joly
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Maxillo-facial Surgery, Tours, France
| | - Grégoire Boulouis
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Neuroradiology and Interventional Radiology, Tours, France
| | - Laurent Guibaud
- Service d'Imagerie, Consultation Multidisciplinaire des Angiomes, Centre de Compétence National Malformations Vasculaires Superficielles, Hôpital Femme Mère Enfant, Université Claude Bernard Lyon 1, Lyon-Bron, France
| | - Elsa Tavernier
- University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France; CHRU Tours, Clinical Investigation Center INSERM 1415, Tours, France
| | - Stéphanie Mallet
- University Hospital Center of Marseille, Department of Dermatology, Marseille, France
| | - Clément Marcelin
- University Hospital Center of Bordeaux, Department of Radiology, Bordeaux, France
| | - Juliette Miquel
- University Hospital Center of La Réunion, Department of Pediatric Dermatology, Saint-Pierre, La Réunion, France
| | - Ludovic Martin
- University Hospital Center of Angers, Department of Dermatology, Angers, France
| | | | - Laurence Gusdorf
- University Hospital Center of Reims, Department of Dermatology, Reims, France
| | - Claire Abasq
- University Hospital Center of Brest, Department of Dermatology, Brest, France
| | - Ali Dadban
- University Hospital Center of Amiens, Department of Dermatology, Amiens, France
| | | | - Pierre Vabres
- University of Bourgogne, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Dijon, France
| | - Denis Herbreteau
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Neuroradiology and Interventional Radiology, Tours, France
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Necker), University Hospital Necker-Enfants Malades, Paris, France
| | - Michel Wassef
- University Hospital of Lariboisière, AP-HP, Department of Pathology, Paris, France
| | - Annabel Maruani
- CHRU Tours, Department of Dermatology, Unit of Pediatric Dermatology, Tours, France; Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France.
| |
Collapse
|
6
|
Godeau M, Shourick J, Dreyfus I, Casassa É, Bergeron A, Severino-Freire M, Granier Tournier C, Malloizel-Delaunay J, Boccara O, Aubert H, Maruani A, Chiaverini C, Labrèze C, Mazereeuw-Hautier J. cLFM‐Qol
: a specific quality of life measurement tool for children from 11 to 15 years with low‐flow malformations. J Eur Acad Dermatol Venereol 2023. [PMID: 36972023 DOI: 10.1111/jdv.19061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 03/08/2023] [Indexed: 03/29/2023]
Abstract
BACKGROUND Low-flow malformations (LFMs) are rare diseases with a significant impact on health-related quality of life (HRQoL), especially in children. No disease-specific questionnaire is available for children with LFMs. OBJECTIVE To develop and validate a specific HRQoL questionnaire for children from 11 to 15 years old suffering from LFMs. METHODS A preliminary questionnaire based on a verbatim from focus groups was created and sent to children from 11 to 15 years old suffering from LFMs, together with a dermatology specific and a generic HRQoL questionnaire (cDLQI and EQ-5D-Y). RESULTS A total of 75 from 201 included children responded to the questionnaires. The final version of the questionnaire (cLFM-QoL) included 15 questions and was not divisible into subscales. It demonstrated excellent internal consistency (cronbach 0.89), convergent validity and readability (SMOG 6.04). cLFM-QoL mean score (+ SD) was 12.9/45 (8.03) for all grades of severity, for mild 8.22/45 (7.5), moderate 14.03/45 (8.35), severe 12.35/45 (6.59) or very severe patients 20.7/45 (3.39) (p 0.006). CONCLUSION cLFM-QoL is a validated short and easy to use specific questionnaire with excellent psychometric capacities. It will be suitable for any children 11 to 15 with LFMs, in daily practice or clinical trials.
Collapse
Affiliation(s)
- Marion Godeau
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| | - Jason Shourick
- Pôle santé publique et médecine sociale, Epidemiology Department, CHU Toulouse, Faculté de médecine de Purpan, Occitanie, Toulouse, France
| | - Isabelle Dreyfus
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| | - Éline Casassa
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| | - Anaïs Bergeron
- Centre d'Etudes et de Recherches en Psychopathologie et psychologie de la Santé, Psychopathology Department, Toulouse II Jean Jaurès University, Occitanie, Toulouse, France
| | - Maella Severino-Freire
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| | - Céline Granier Tournier
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| | | | - Olivia Boccara
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Dermatology Department, Necker-Enfants Malades Hospitals, Île-de-France, Paris, France
| | - Hélène Aubert
- Dermatology Derpartment, CHU Nantes, Nantes, Pays de la Loire, France
| | - Annabel Maruani
- Dermatology Department, CHRU Tours, François Rabelais University, Centre, Tours, France
| | - Christine Chiaverini
- Dermatology Department, CHU Nice, Archet 2 Hospital, Provence-Alpes-Côte d'Azu, Nice, France
| | - Christine Labrèze
- Pediatric Dermatology Unit, CHU Bordeaux, Pellegrin children's Hospital, Aquitaine, Bordeaux, France
| | - Juliette Mazereeuw-Hautier
- Reference Center for Rare Skin Diseases, Dermatology Department, CHU toulouse, Paul Sabatier University, Occitanie, Toulouse, France
| |
Collapse
|
7
|
Orly J, Bisdorff A, Joly A, Edee AE, Tavernier E, Herbreteau D, Boccara O, Wassef M, Maruani A. Characteristics, Natural Course and Treatment of Intramuscular Capillary-type Haemangioma: A Systematic Literature Review. Acta Derm Venereol 2023; 103:adv00893. [PMID: 36939537 PMCID: PMC10041649 DOI: 10.2340/actadv.v103.4432] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Accepted: 11/29/2022] [Indexed: 03/21/2023] Open
Abstract
Intramuscular capillary-type haemangiomas (ICTH) are rare vascular anomalies that can easily be misdiagnosed as other entities. A systematic review was performed of all cases of ICTH in the literature since its first description in 1972. An adjudication committee reviewed cases to include only ICTHs. Among 1,143 reports screened, 43 were included, involving 75 patients. The most frequent differential diagnosis was intramuscular venous malformations. The mean age of patients at diagnosis was 21.2 years. ICTH was mainly described as a gradually increasing mass (81.8%), painless (73.9%), that could occur anywhere in the body but most frequently on the head and neck (44.0%). Magnetic resonance imaging (MRI) was mainly used for diagnosis (69.1%) and displayed specific features. The most frequent treatment was complete surgical removal (73.9%), which could be preceded by embolization, and led to complete remission without recurrence in all but 1 case.
Collapse
Affiliation(s)
- Jordan Orly
- CHRU Tours, Department of Dermatology, Unit of Pediatric dermatology, Tours, France; Reference center for genodermatoses and rare skin diseases (MAGEC-Tours), Tours.
| | - Annouk Bisdorff
- 3Reference center for vascular anomalies FAVA-multi, University Hospital of Lariboisière; Coordinator of the constitutive center for superficial arteriovenous malformations in children and adults; AP-HP, Department of Neuroradiology, Paris, France
| | - Aline Joly
- Reference center for genodermatoses and rare skin diseases (MAGEC-Tours), Tours, France; Reference center for vascular anomalies FAVA-multi, University Hospital of Lariboisière; Coordinator of the constitutive center for superficial arteriovenous malformations in children and adults; AP-HP, Department of Neuroradiology, Paris, France; CHRU Tours, Department of Maxillo-facial surgery, Tours, France
| | - Afi-Emiliène Edee
- Reference center for genodermatoses and rare skin diseases (MAGEC-Tours), Tours, France
| | - Elsa Tavernier
- University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France; CHRU Tours, Clinical Investigation Center INSERM 1415, Tours, France
| | | | - Olivia Boccara
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC-Necker), University Hospital Necker-Enfants Malades, Paris, France
| | - Michel Wassef
- Department of Pathology, University Hospital of Lariboisière, AP-HP, Paris, France
| | - Annabel Maruani
- CHRU Tours, Department of Dermatology, Unit of Pediatric dermatology, Tours, France; Reference center for genodermatoses and rare skin diseases (MAGEC-Tours), Tours, France; University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France
| |
Collapse
|
8
|
Roupie AL, Lafont E, Fraitag S, Ferroni A, Lécuyer H, Boccara O, Bessède E, Lehours P, Lefrère F, Lortholary O. Recurrent Cellulitis Revealing Helicobacter cinaedi in Patient on Ibrutinib Therapy, France. Emerg Infect Dis 2023; 29:640-641. [PMID: 36823687 PMCID: PMC9973678 DOI: 10.3201/eid2903.221329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Helicobacter cinaedi bacteremia caused recurring multifocal cellulitis in a patient in France who had chronic lymphocytic leukemia treated with ibrutinib. Diagnosis required extended blood culture incubation and sequencing of the entire 16S ribosomal RNA gene from single bacterial colonies. Clinicians should consider H. cinaedi infection in cases of recurrent cellulitis.
Collapse
|
9
|
Maruani A, Moineau AG, Boccara O, Mazereeuw-Hautier J, Leducq S, Bessis D, Guibaud L, Vabres P, Mallet S, Barbarot S, Chiaverini C, Droitcourt C, Bursztejn AC, Lengelle C, Woillard JB, Herbreteau D, Le Touze A, Binet A, Morel B, Bourgoin H, Gissot V, Giraudeau B, Gruel Y, Tavernier E, Rollin J. Vascular endothelial growth factor, tissue factor, coagulation and fibrinolysis markers in slow-flow vascular malformations: a prospective study of treatment with sirolimus. Br J Dermatol 2023; 188:152-154. [PMID: 36689523 DOI: 10.1093/bjd/ljac028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 09/21/2022] [Accepted: 09/24/2022] [Indexed: 01/22/2023]
Abstract
Slow-flow vascular malformations (VMs), especially those with venous components, can be complicated by localized intravascular coagulopathy (LIC), responsible for pain and impaired quality of life. Several studies have shown the effectiveness of mTOR inhibitors (especially sirolimus) on slow-flow VMs but its effect on coagulation has been poorly studied, especially in children. Our study shows that venous and combined VMs are associated with coagulation abnormalities and provides novel evidence that sirolimus improves coagulopathy in venous malformations. However we did not clearly evidence predictive biomarkers of response to sirolimus but this is the first study attempting to highlight predictive markers of response to sirolimus.
Collapse
Affiliation(s)
- Annabel Maruani
- University of Tours, University of Nantes, INSERM, SPHERE U1246, Tours, France
- CHRU Tours, Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France
| | - Anne-Guillemette Moineau
- CHRU Tours, Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jérôme Rollin
- University of Tours, CHRU Tours, Department of Hemostasis, Tours, France
| |
Collapse
|
10
|
Leboulanger N, Bisdorff A, Boccara O, Dompmartin A, Guibaud L, Labreze C, Lagier J, Lebrun-Vignes B, Herbreteau D, Joly A, Malloizel-Delaunay J, Martel A, Munck S, Saint-Aubin F, Maruani A. French national diagnosis and care protocol (PNDS, protocole national de diagnostic et de soins): cystic lymphatic malformations. Orphanet J Rare Dis 2023; 18:10. [PMID: 36639640 PMCID: PMC9837920 DOI: 10.1186/s13023-022-02608-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 12/29/2022] [Indexed: 01/15/2023] Open
Abstract
Cystic lymphatic malformations (LMs) are rare chronic conditions which management differs according to the type (macrocystic LMs, microcystic LMs or both). Studies are lacking due to rarity of the pathology. We aimed to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), to provide health professionals with free open access synthesis on optimal management and care of patients with LMs ( https://www.has-sante.fr/upload/docs/application/pdf/2021-03/malformations_lymphatiques_kystiques_-_pnds.pdf ). The process included a critical review of the literature and multidisciplinary expert consensus. LMs are congenital but are not always discovered at birth. Nearly 75% of them are located in the head and neck because of the highly dense lymphatic system in this region. Physical examination (showing painless masses with normal skin color and depressible consistency, or cutaneous/mucosal lymphangiectasia) and color Doppler ultrasonography, usually allow for diagnosis. MRI (involving T2 sequences with fat saturation in at least two spatial planes) is the tool of choice for evaluating anatomical extension, characterizing lesions (microcystic and macrocystic), and before considering therapeutic management. A biopsy, coupled to a blood sample, can also be used for molecular biology analyses, to search for activating mutations of the PIK3CA gene, particularly with LM integrating in a syndromic form (CLOVES or Klippel-Trenaunay syndrome) but also in certain isolated (or common) LMs. The spontaneous evolution of LMs, in particular microcystic forms, is often toward progressive aggravation, with an increase in the number of vesicles, thickening, increased oozing and bleeding, while pure macrocystic LMs may regress due to "natural sclerosis", i.e. fibrosis secondary to an inflammatory reorganization after common infantile infections. In case of voluminous LMs or syndromic forms, functional and psychological repercussions can be major, deteriorating the patient's quality of life. LMs must be treated by physicians integrated in multidisciplinary teams, and be personalized. Management is a life-long process that involves one or several of these therapies: conservative management, physical therapy (compression), sclerotherapy, surgery, drugs such as mTOR inhibitors (sirolimus), that has shown efficacy in decreasing the volume of LMs, and, more recently, PI3K-inhibitors in syndromic forms. Psychological and social support is necessary, taking into account the patient and his family.
Collapse
Affiliation(s)
- Nicolas Leboulanger
- Otolaryngology - Head and Neck Surgery Department. National Reference Center for Rare Otolaryngological Malformations (MALO), Necker Enfants Malades Hospital, 149 Rue de Sèvres, 75015, Paris, France. .,INSERM U955, Paris Cité University. ERN Cranio, Paris, France.
| | - Annouk Bisdorff
- grid.411296.90000 0000 9725 279XDepartment of Interventional Radiology, Lariboisière Hospital, Paris, France
| | - Olivia Boccara
- grid.412134.10000 0004 0593 9113Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), Necker Enfants Malades Hospital, Paris, France
| | - Anne Dompmartin
- grid.411149.80000 0004 0472 0160Department of Dermatology, CHU Côte de Nacre, Caen, France
| | - Laurent Guibaud
- grid.413852.90000 0001 2163 3825Department of Radiology, Hôpital Mère-Enfant, CHU de Lyon, Lyon, France
| | - Christine Labreze
- grid.42399.350000 0004 0593 7118Department of Dermatology, Pellegrin Hospital, CHU de Bordeaux, Bordeaux, France
| | - Jacques Lagier
- grid.410528.a0000 0001 2322 4179Department of Ophthalmology, CHU de Nice, Nice, France
| | - Bénédicte Lebrun-Vignes
- grid.411439.a0000 0001 2150 9058Pharmacovigilance Unit, AP-HP, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France
| | - Denis Herbreteau
- grid.411167.40000 0004 1765 1600Department of Neuroradiology and Interventional Radiology - Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU de Tours, Tours, France
| | - Aline Joly
- grid.411167.40000 0004 1765 1600Department of Maxillofacial Surgery - Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU de Tours, 37044 Tours, Cedex 9 France
| | - Julie Malloizel-Delaunay
- grid.411175.70000 0001 1457 2980Department of Vascular Medicine, Rangueil Hospital, CHU de Toulouse, Toulouse, France
| | - Arnaud Martel
- grid.410528.a0000 0001 2322 4179Department of Ophthalmology, CHU de Nice, Nice, France
| | - Stéphane Munck
- grid.460782.f0000 0004 4910 6551Département d’enseignement et de Recherche en Médecine Générale, Retines, Healthy, Université Côte d’Azur, 06000 Nice, France
| | | | - Annabel Maruani
- grid.411167.40000 0004 1765 1600Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU de Tours, Tours, France ,grid.12366.300000 0001 2182 6141INSERM 1246 ‑ SPHERE, Universities of Tours and Nantes, 37000 Tours, France
| |
Collapse
|
11
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Samimi M, Morel B, Caille A, Maruani A, Leducq S. Quality of life of children with capillary malformations of the lower limbs: Evolution and associated factors. Data from the French national paediatric cohort, CONAPE. Ann Dermatol Venereol 2022; 149:271-275. [PMID: 35810006 DOI: 10.1016/j.annder.2022.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 02/16/2022] [Accepted: 03/30/2022] [Indexed: 01/19/2023]
Affiliation(s)
- J Robert
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France
| | - A Marchand
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France
| | - J Mazereeuw-Hautier
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), Hospital Larrey, University Hospital Center of Toulouse, 31059 Toulouse Cedex 9, France
| | - O Boccara
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), France Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France
| | - L Martin
- Department of Dermatology, University Hospital Center of Angers, 49000 Angers, France
| | - C Chiaverini
- Department of Dermatology, University Hospital Center of Nice, 06000 Nice, France
| | - N Beneton
- Department of Dermatology, Hospital Center of le Mans, 72000 Le Mans, France
| | - P Vabres
- Department of Dermatology, University Hospital Center of Dijon, Reference center for genodermatoses and rare skin diseases (MAGEC), 21000 Dijon, France
| | - X Balguerie
- Department of Dermatology, University Hospital Center of Rouen, 76000 Rouen, France
| | - P Plantin
- Department of Dermatology, Hospital Center of Quimper, 29000 Quimper, France
| | - D Bessis
- Department of Dermatology, University Hospital Center of Montpellier, 34000 Montpellier, France
| | - S Barbarot
- Department of Dermatology, University Hospital Center of Nantes, 44000 Nantes, France
| | - A Dadban
- Department of Dermatology, University Hospital Center of Amiens, 80000 Amiens, France
| | - C Droitcourt
- Department of Dermatology, University Hospital Center of Rennes, 35000 Rennes, France
| | - M Samimi
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France
| | - B Morel
- CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Department of Pediatric Radiology, 37000 Tours, France
| | - A Caille
- CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - A Maruani
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - S Leducq
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France.
| | | |
Collapse
|
12
|
Welfringer-Morin A, Barroil M, Fraitag S, Szablewski V, Boccara O, Lacour JP, Chiaverini C, Bagot M, Ram-Wolff C, Vignon-Pennamen MD, Dalle S, D'incan M, Amatore F, Beylot-Barry M, Vergier B, Mazereeuw-Hautier J, Tedbirt B, Quereux G, Carpentier O, Skowron F, Bertrand Y, Van Eeckhout P, Dekeuleneer V, Nardin C, Adamski H, Ingen-Housz-Oro S, Dereure O, Bodemer C. Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients. Dermatology 2022; 239:132-139. [PMID: 36349768 DOI: 10.1159/000526788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 06/21/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. METHODS This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients' clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed. RESULTS Forty-six patients were included (median age at diagnosis: 11 years; M:F sex ratio: 3:1) with 39 (85%) followed for at least 12 months. Thirty-nine patients (85%) had stage I MF. Hypopigmented patches were observed in 48% and folliculotropism in 43% patients. Immunophenotype of the skin infiltrate was predominantly CD8+ in 17% of patients. Initial management included a wait-and-see strategy in 6/39 (15%), skin-directed treatment in 27 (69%), and systemic treatment in 6 (15%) patients, respectively, with partial or complete clinical response (PR or CR) observed in 28 patients (72%). 14/39 patients (36%) relapsed after initial response. After a median follow-up period of 54 months, disease status at last news was PR or CR in 31/39 (79%), stable disease in 6 (15%), and progression in 2 (5%) patients. Histological transformation was observed in 3/39 (8%). Of the 15 patients followed until adulthood, 13 (87%) had persistent MF. DISCUSSION This survey confirms the high frequency of hypopigmented and folliculotropic lesions and of CD8+ immunophenotype compared to adult MF patients. The long-term course is usually indolent but transformation may occur sometimes long after disease onset and the disease may persist during adulthood.
Collapse
Affiliation(s)
- Anne Welfringer-Morin
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France,
| | - Marion Barroil
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Sylvie Fraitag
- Department of Pathology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | | | - Olivia Boccara
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | - Jean-Philippe Lacour
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Christine Chiaverini
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Martine Bagot
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | | | - Stéphane Dalle
- Department of Dermatology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Michel D'incan
- Department of Dermatology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Florent Amatore
- Department of Dermatology, Hospital la Timone, Université Aix-Marseille, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Marie Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | | | | | - Gaelle Quereux
- Department of Dermatology, Hotel Dieu, CHU de Nantes, Nantes, France
| | - Olivier Carpentier
- Department of Dermatology, Hospital Claude Huriez, CHRU Lille, Lille, France
| | | | - Yves Bertrand
- Department of Hematology, Institut d'hématologie et oncologie pediatrique, Lyon, France
| | - Pascal Van Eeckhout
- Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Valérie Dekeuleneer
- Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Charlee Nardin
- Department of Dermatology, CHU de Besancon, INSERM UMR 1098, Université de Franche-Comté, Besancon, France
| | - Henri Adamski
- Department of Dermatology, CHU Pontchaillou, Rennes, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Hospital Henri Mondor, APHP, University Paris Est Créteil EpiDermE, Creteil, France
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Christine Bodemer
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| |
Collapse
|
13
|
Boccara O, Dangien A, Fitoussi F, Ducou Le Pointe H, Coulomb L'Hermine A, Fraitag S, Lorrot M. Bone kaposiform hemangioendothelioma: A rare entity dramatically improved by sirolimus. J Paediatr Child Health 2022; 58:1676-1679. [PMID: 35138010 DOI: 10.1111/jpc.15897] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 09/24/2021] [Accepted: 01/04/2022] [Indexed: 01/05/2023]
Affiliation(s)
- Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Ambre Dangien
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Franck Fitoussi
- Department of Orthopedic Surgery, Hôpital Universitaire Trousseau, Sorbonne Université, APHP, Paris, France
| | | | | | - Sylvie Fraitag
- Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Mathie Lorrot
- Department of Pediatrics, Hôpital Universitaire Trousseau, Sorbonne Université, APHP, Paris, France
| |
Collapse
|
14
|
Labonnelie A, Soupre V, Maruani A, Cisternino S, Hadj‐Rabia S, Boccara O. Management of sirolimus treatment for tumors associated with Kasabach‐Merritt phenomenon. J Eur Acad Dermatol Venereol 2022; 36:e586-e588. [DOI: 10.1111/jdv.18077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 03/04/2022] [Indexed: 11/30/2022]
Affiliation(s)
- A. Labonnelie
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| | - V. Soupre
- Department of pediatric maxillo‐facial and plastic surgery University Hospital of Necker‐Enfants Malades, APHP5 Paris France
| | - A. Maruani
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) Universities of Nantes and Tours, INSERM 1246‐SPHERE; CHRU Tours Tours France
| | - S. Cisternino
- Department of pharmacy APHP5, University Hospital Necker – Enfants Malades University of Paris, Faculté de Pharmacie, Optimisation Thérapeutique en Neuropsychopharmacologie F‐75006 Paris France
- INSERM UMR‐S 1144 Paris France
| | - S. Hadj‐Rabia
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| | - O. Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| |
Collapse
|
15
|
Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C. Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. J Eur Acad Dermatol Venereol 2022; 36:610-614. [PMID: 35000215 DOI: 10.1111/jdv.17907] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 11/23/2021] [Accepted: 12/07/2021] [Indexed: 01/08/2023]
Abstract
BACKGROUND The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied. OBJECTIVES The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of age. METHODS This retrospective case series study was conducted from January 2008 to June 2020 using data from medical files, patient examinations and appointments spanning 6 years. To be included, patients should present SFIH and have previously received propranolol. A complete physical examination, magnetic resonance imaging (MRI) of the head, echocardiography and ophthalmologic examination should have been performed. Neurodevelopmental features were divided into cognition, audition, vision, orality, motor skills and the occurrence of new symptoms. RESULTS Thirty children with SFIH were included. Of these, 11 presented criteria of PHACES. Evaluation of neurodevelopmental features of the children at 6 years of age showed learning difficulties in one case but grade skipping in three cases. There were six cases of unilateral hearing loss that had not been diagnosed at birth, two of oral difficulties and one of minor hypotonia. Early headache was primarily reported as the main new outcome. All children were treated with propranolol, with three following oral steroid therapy. No severe adverse effects were reported. The median length of treatment with propranolol was 16 months, and the median age at treatment cessation was 21 months. Analysis based on segment implication showed the median length of treatment to vary from 12 months (if S3 was spared) to 25 months (if at least S3 was involved). Vascular laser therapy was used in 16 patients (53.3%) and surgery in four. CONCLUSION In this case series, children with SFIH, including patients with PHACES criteria, presented a good tolerance of propranolol, as well as encouraged neurodevelopmental data. Segmental implication appears to have a significant impact on treatment duration and associated complications.
Collapse
Affiliation(s)
- O Letertre
- Department of Pediatric Dermatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - O Boccara
- Department of Pediatric Dermatology, Hôpital Necker, APHP Paris, Paris, France
| | - S Prey
- Department of Pediatric Dermatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - J-M Pedespan
- Department of Pediatric Neurology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - F Boralevi
- Department of Pediatric Dermatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - C Léauté-Labrèze
- Department of Pediatric Dermatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| |
Collapse
|
16
|
Boccara O, Mazereeuw J, Martin L, Bessis D, Hubiche T, Chiaverini C, Dompmartin A, Mallet S, Miquel J, Aubert H, Puzenat E, Abasq C, Gusdorf L, Hadj-Rabia S, Maruani A. Central nervous system screening in capillary malformation-arteriovenous malformation syndrome: an observational study. J Am Acad Dermatol 2021; 87:914-916. [PMID: 34954287 DOI: 10.1016/j.jaad.2021.12.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 12/07/2021] [Accepted: 12/15/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France.
| | - Juliette Mazereeuw
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases, Paul Sabatier University Toulouse, Larrey Hospital, Toulouse, France
| | | | - Didier Bessis
- Department of Dermatology, CHU Montpellier, Montpellier, France
| | | | | | | | | | - Juliette Miquel
- Unit of Pediatric Dermatology, CHU Reunion, Saint Pierre, France
| | - Hélène Aubert
- Department of Dermatology, CHU Nantes, Nantes, France
| | - Eve Puzenat
- Department of Dermatology, CHU Besançon, Besançon, France
| | - Claire Abasq
- Department of Dermatology, CHU Brest, Brest, France
| | | | - Smail Hadj-Rabia
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Annabel Maruani
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Universities of Nantes and Tours, Inserm 1246-SPHERE, CHU Tours, Tours, France
| |
Collapse
|
17
|
Maruani A, Tavernier E, Boccara O, Mazereeuw-Hautier J, Leducq S, Bessis D, Guibaud L, Vabres P, Carmignac V, Mallet S, Barbarot S, Chiaverini C, Droitcourt C, Bursztejn AC, Lengellé C, Woillard JB, Herbreteau D, Le Touze A, Joly A, Léauté-Labrèze C, Powell J, Bourgoin H, Gissot V, Giraudeau B, Morel B. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatol 2021; 157:1289-1298. [PMID: 34524406 DOI: 10.1001/jamadermatol.2021.3459] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Sirolimus is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is lacking. Objective To assess the efficacy and safety of sirolimus for children with slow-flow vascular malformations to better delineate the indications for treatment. Design, Setting and Participants This multicenter, open-label, observational-phase randomized clinical trial included 59 children aged 6 to 18 years with a slow-flow vascular malformation who were recruited between September 28, 2015, and March 22, 2018, in 11 French tertiary hospital centers. Statistical analysis was performed on an intent-to-treat basis from December 4, 2019, to November 10, 2020. Interventions Patients underwent an observational period, then switched to an interventional period when they received oral sirolimus (target serum levels, 4-12 ng/mL). The switch time was randomized from month 4 to month 8, and the whole study period lasted 12 months for each patient. Main Outcomes and Measures The primary outcome was change in the volume of vascular malformations detected on magnetic resonance imaging scan (with centralized interpretation) per unit of time (ie, between the interventional period and the observational period). Secondary outcomes included subjective end points: pain, bleeding, oozing, quality of life, and safety. Results Among the participants (35 girls [59.3%]; mean [SD] age, 11.6 [3.8] years), 22 (37.3%) had a pure venous malformation, 18 (30.5%) had a cystic lymphatic malformation, and 19 (32.2%) had a combined malformation, including syndromic forms. Variations in the volume of vascular malformations detected on magnetic resonance imaging scans associated with the duration period were not overall significantly different between the interventional period and the observational period (all vascular malformations: mean [SD] difference, -0.001 [0.007]; venous malformations: mean [SD] difference, 0.001 [0.004]; combined malformations: mean [SD] difference, 0.001 [0.009]). However, a significant decrease in volume was observed for children with pure lymphatic malformations (mean [SD] difference, -0.005 [0.005]). Overall, sirolimus had positive effects on pain, especially for combined malformations, and on bleeding, oozing, self-assessed efficacy, and quality of life. During sirolimus treatment, 56 patients experienced 231 adverse events (5 serious adverse events, none life-threatening). The most frequent adverse event was an oral ulcer (29 patients [49.2%]). Conclusions and Relevance This observational-phase randomized clinical trial allows for clarifying the goals of patients and families when starting sirolimus therapy for children older than 6 years. Pure lymphatic malformations seem to be the best indication for sirolimus therapy because evidence of decreasing lymphatic malformation volume per unit of time, oozing, and bleeding and increasing quality of life was found. In combined malformations, sirolimus significantly reduced pain, oozing, and bleeding. Benefits seemed lower for pure venous malformations than for the 2 other subgroups, also based on symptoms. Trial Registration ClinicalTrials.gov Identifier: NCT02509468; clinicaltrialsregister.eu Identifier: 2015-001096-43.
Collapse
Affiliation(s)
- Annabel Maruani
- University of Tours, University of Nantes, Institut National de la Santé et de la Recherche Médicale, SPHERE U1246, Tours, France.,Centre Hospitalier Régional Universitaire Tours, Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Tours), Tours, France.,Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center 1415, Tours, France
| | - Elsa Tavernier
- University of Tours, University of Nantes, Institut National de la Santé et de la Recherche Médicale, SPHERE U1246, Tours, France.,Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center 1415, Tours, France
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Necker), University Hospital Necker-Enfants Malades, Paris, France
| | | | - Sophie Leducq
- University of Tours, University of Nantes, Institut National de la Santé et de la Recherche Médicale, SPHERE U1246, Tours, France.,Centre Hospitalier Régional Universitaire Tours, Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Tours), Tours, France
| | - Didier Bessis
- Department of Dermatology, University Hospital Center of Montpellier, Montpellier, France
| | - Laurent Guibaud
- University Hospital Center of Lyon, Consultation Multidisciplinaire Lyonnaise des Angiomes, Lyon, France
| | - Pierre Vabres
- Department of Dermatology, University Hospital Center of Dijon, Dijon, France
| | - Virginie Carmignac
- Department of Dermatology, University Hospital Center of Dijon, Dijon, France
| | - Stéphanie Mallet
- Department of Dermatology, University Hospital Center of Marseille, Marseille, France
| | - Sébastien Barbarot
- Department of Dermatology, University Hospital Center of Nantes, Nantes, France
| | | | | | | | - Céline Lengellé
- Centre Hospitalier Régional Universitaire Tours, Department of Clinical Pharmacology, Regional Pharmacovigilance Center, Tours, France
| | - Jean-Baptiste Woillard
- Centre Hospitalier Universitaire Limoges, Department of Pharmacology and Toxicology, University of Limoges, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 850, Limoges, France
| | - Denis Herbreteau
- University of Tours, Centre Hospitalier Régional Universitaire Tours, Department of Neuroradiology, Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Tours), Tours, France
| | - Anne Le Touze
- Centre Hospitalier Régional Universitaire Tours, Department of Pediatric Surgery, Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Tours), Tours, France
| | - Aline Joly
- Centre Hospitalier Régional Universitaire Tours, Department of Pediatric Maxillofacial Surgery, Reference Center for Genodermatoses and Rare Skin Diseases (Maladies Génétiques rares à Expression Cutanée-Tours), Tours, France
| | | | - Julie Powell
- Department of Pediatric Dermatology, Hospital Sainte-Justine, Montréal, Québec, Canada
| | - Hélène Bourgoin
- Centre Hospitalier Régional Universitaire Tours, Department of Pharmacy, Tours, France
| | - Valérie Gissot
- Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center 1415, Tours, France
| | - Bruno Giraudeau
- University of Tours, University of Nantes, Institut National de la Santé et de la Recherche Médicale, SPHERE U1246, Tours, France.,Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center 1415, Tours, France
| | - Baptiste Morel
- University of Tours, Centre Hospitalier Régional Universitaire Tours, Department of Pediatric Radiology, Tours, France
| |
Collapse
|
18
|
Delestre F, Venot Q, Bayard C, Fraissenon A, Ladraa S, Hoguin C, Chapelle C, Yamaguchi J, Cassaca R, Zerbib L, Magassa S, Morin G, Asnafi V, Villarese P, Kaltenbach S, Fraitag S, Duong JP, Broissand C, Boccara O, Soupre V, Bonnotte B, Chopinet C, Mirault T, Legendre C, Guibaud L, Canaud G. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients. Sci Transl Med 2021; 13:eabg0809. [PMID: 34613809 DOI: 10.1126/scitranslmed.abg0809] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Florence Delestre
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Quitterie Venot
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Charles Bayard
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Antoine Fraissenon
- INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France.,Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, HCL, Bron, 69500, France.,Service de Radiologie Mère-Enfant, Hôpital Nord, Saint Etienne, 42000, France
| | - Sophia Ladraa
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Clément Hoguin
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Célia Chapelle
- INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France.,Unité d'hypercroissance dysharmonieuse et anomalies vasculaires, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Junna Yamaguchi
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Rubina Cassaca
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Lola Zerbib
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Sato Magassa
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Gabriel Morin
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France
| | - Vahid Asnafi
- Université de Paris, Paris, 75006, France.,Laboratoire d'Oncohématologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Patrick Villarese
- Laboratoire d'Oncohématologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Sophie Kaltenbach
- Université de Paris, Paris, 75006, France.,Laboratoire d'Oncohématologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Sylvie Fraitag
- Département d'Anatomopathologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Jean-Paul Duong
- Université de Paris, Paris, 75006, France.,Département d'Anatomopathologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | | | - Olivia Boccara
- Service de Dermatologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Véronique Soupre
- Service de Chirurgie Maxillo-faciale Pédiatrique, Hôpital Necker-Enfants Malades, AP-HP, 75015, Paris, France
| | - Bernard Bonnotte
- Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Dijon, 21000, France
| | - Caroline Chopinet
- Service d'Exploration Fonctionnelle Cardiovasculaire, CHU Lille, Lille, 59000, France
| | - Tristan Mirault
- Service de Médecine Vasculaire, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France
| | - Christophe Legendre
- Université de Paris, Paris, 75006, France.,Service de Néphrologie et Transplantation Adultes, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| | - Laurent Guibaud
- Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, HCL, Bron, 69500, France
| | - Guillaume Canaud
- Université de Paris, Paris, 75006, France.,INSERM U1151, Institut Necker-Enfants Malades, Paris, 75015, France.,Unité d'hypercroissance dysharmonieuse et anomalies vasculaires, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France.,Service de Néphrologie et Transplantation Adultes, Hôpital Necker-Enfants Malades, AP-HP, Paris, 75015, France
| |
Collapse
|
19
|
Fraitag S, Boccara O. What to Look Out for in a Newborn with Multiple Papulonodular Skin Lesions at Birth. Dermatopathology (Basel) 2021; 8:390-417. [PMID: 34449594 PMCID: PMC8395860 DOI: 10.3390/dermatopathology8030043] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2021] [Revised: 08/11/2021] [Accepted: 08/12/2021] [Indexed: 12/17/2022] Open
Abstract
Multiple papulonodular skin lesions at birth can indicate the presence of various benign and malignant disorders. Although the lesions’ clinical aspect (color and consistency, in particular) may steer the clinician towards one disorder or another (infantile myofibromatosis, xanthogranuloma, or metastatic neuroblastoma), the diagnosis can only be confirmed by the histopathologic assessment of a biopsy. In neonates, a rapid but accurate diagnosis is critical because skin lesions may be the first manifestation of a malignant disorder like leukemia cutis or metastatic neuroblastoma. Here, we review the various disorders that may manifest themselves as multiple skin lesions at birth.
Collapse
Affiliation(s)
- Sylvie Fraitag
- Department of Pathology, Necker-Enfants Malades Hospital, APHP, 75015 Paris, France
- Correspondence:
| | - Olivia Boccara
- Department of Dermatology, Necker-Enfants Malades Hospital, APHP, 75015 Paris, France;
| |
Collapse
|
20
|
Vermersch C, Boccara O, Chiaverini C, Mazereeuw-Hautier J, Sigg N, Mallet S, Vabres P, Herbreteau D, Le Touze A, Maruani A, Leducq S. Health care transition for patients with vascular malformations: a French multicenter cross-sectional study. Orphanet J Rare Dis 2021; 16:352. [PMID: 34362421 PMCID: PMC8349005 DOI: 10.1186/s13023-021-01970-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2021] [Accepted: 07/19/2021] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Health care transition (i.e., transition from pediatric to adult care) is challenging in chronic conditions but has been poorly studied in rare chronic skin diseases. We investigated the proportion of lost to follow-up among patients with superficial vascular malformations after health care transition. We also collected patients' opinions. This prospective, multicenter, cross-sectional study was performed at 7 French hospitals. We included patients aged 19-25 years, who were followed for a superficial vascular malformation before age 16, and who had completed the transition period in 2020. Data were collected from medical records and a questionnaire was sent to included patients asking about the health care transition. RESULTS Among the 90 patients included, 41 (46%) were lost to follow-up after health care transition period. The age at diagnosis was significantly higher for lost to follow-up than non- lost to follow-up patients. The lost to follow-up proportion was similar between patients who changed and did not change hospitals during the transition. Responses to the questionnaire were obtained for 47 of 90 patients (52.2% response rate); most were satisfied with their care (n = 31/36, 86.1%); however, a lack of psychological support was reported. CONCLUSIONS Health care transition is associated to a high rate of lost to follow-up. Early management seems associated to less lost to follow-up. Further studies are needed to better understand risk factors for a failed health care transition and its consequences.
Collapse
Affiliation(s)
- Camille Vermersch
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de La République, 37044, Tours Cedex 9, France
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Necker-Enfants Malades University Hospital, APHP5, Paris, France.,Imagine Institute, Paris University, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | | | | | - Nina Sigg
- Department of Dermatology, University Hospital Center of Angers, Angers, France
| | - Stéphanie Mallet
- Department of Dermatology, University Hospital Center of Marseille, 13885, Marseille Cedex 5, France
| | - Pierre Vabres
- Department of Dermatology, University Hospital Center of Dijon, Dijon, France
| | - Denis Herbreteau
- Department of Neuroradiology and Interventional Radiology, University Hospital Center of Tours, Tours, France
| | - Anne Le Touze
- Department of Pediatric Surgery, University Hospital Center of Tours, Tours, France
| | - Annabel Maruani
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de La République, 37044, Tours Cedex 9, France.,Universities of Tours and Nantes, INSERM 1246-SPHERE, 37000, Tours, France
| | - Sophie Leducq
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de La République, 37044, Tours Cedex 9, France. .,Universities of Tours and Nantes, INSERM 1246-SPHERE, 37000, Tours, France.
| | | |
Collapse
|
21
|
Bisdorff-Bresson A, Eyries M, Boccara O. Congenital vascular lesions, could MAPK and PI3K inhibitors pave the way to new therapies? Curr Opin Oncol 2021; 33:95-100. [PMID: 33481427 DOI: 10.1097/cco.0000000000000712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW Superficial vascular anomalies are a heterogeneous group of malformative and tumoral lesions, developed from various types of abnormal lymphatic and/or blood vessels. They are mostly benign but their clinical evolution can lead to dramatic cosmetic concern, functional impairment and even life-threatening conditions. Until recently, treatments relied on invasive procedures such as embotherapy/sclerotherapy and/or surgery. Recent molecular findings pave the way of new medical therapies. RECENT FINDINGS Two main signaling pathways PI3K-AKT-mTOR and RAS-MAPK-ERK are now identified to encounter for the causative pathogenic genetic variants of most vascular anomalies. Involved genes are also responsible for several common neoplasms for which targeted therapies are already available or under development. Repurposing treatment strategy is considered for vascular anomalies treatment with promising results. SUMMARY The mTOR inhibitor sirolimus is the most used targeted therapy so far but new molecules are tested currently.
Collapse
Affiliation(s)
- Annouk Bisdorff-Bresson
- Lariboisière Hospital, APHP, Department of Neuroradiology, Vascular Anomalies Clinic, APHP, 2, rue Ambroise Paré, Paris Cedex
| | - Mélanie Eyries
- Pitié-Salpêtrière Hospital, Department of Genetics, 47/83 blvd de l' Hôpital, Paris, APHP
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris- Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, rue de Sèvres, Paris, France
| |
Collapse
|
22
|
Juzot C, Aubert H, Bessis D, Boccara O, Bourrat E, Chiaverini C, Flamant C, Fournet M, Hubiche T, Labrèze C, Martin L, Piram M, Seta V, Finon A, Maruani A, Barbarot S. Transient abdominal telangiectasia of the newborn. Pediatr Dermatol 2021; 38:864-867. [PMID: 34152036 DOI: 10.1111/pde.14620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
We report 20 newborns who developed, at a median age of 7 days, large abdominal patches of radially arranged purplish telangiectasia in a bilateral and symmetrical pattern in relation to the midline, creating a "butterfly wing" pattern. Clinical examination was normal in 13 newborns, six newborns had abdominal distention, and one newborn had poor weight gain due to inadequate breastfeeding. Most lesions spontaneously resolved within 3 months and did not reoccur for 19 newborns. Transient abdominal telangiectasia of the newborn (TATN) appears to be a distinctive entity that has not been previously described.
Collapse
Affiliation(s)
- Cécile Juzot
- Department of Dermatology, University Hospital of Nantes, Nantes, France
| | - Hélène Aubert
- Department of Dermatology, University Hospital of Nantes, Nantes, France
| | - Didier Bessis
- Department of Dermatology, University Hospital of Montpellier, Montpellier, France
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Paris University, Imagine Institute, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | - Emmanuelle Bourrat
- Department of General Pediatrics, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Cyril Flamant
- Department of Neonatal Medicine, University Hospital of Nantes, Nantes, France
| | - Marine Fournet
- Department of Pediatric Dermatology, Hôpital Pellegrin-Enfants, University Hospital of Bordeaux, Bordeaux, France
| | - Thomas Hubiche
- Department of Dermatology, University Hospital of Nice, Nice, France
| | - Christine Labrèze
- Department of Dematology, Pellegrin Children's Hospital, Bordeaux, France
| | - Ludovic Martin
- Department of Dermatology, University Hospital of Angers, Angers, France
| | - Maryam Piram
- Department of Pediatrics, Division of Dermatology, CHU Sainte Justine Research Center, CHU Sainte Justine, University of Montréal, Montréal, QC, Canada
| | - Vannina Seta
- Department of Dermatology, Cochin University Hospital, Paris, France
| | - Antoine Finon
- Department of Dermatology, Orléans Hospital, Orléans, France
| | - Annabel Maruani
- Department of Dermatology, Unit of Pediatric Dermatology, University of Tours, Inserm 1246-SPHERE, CHRU Tours, Tours, France
| | - Sébastien Barbarot
- Department of Dermatology, Nantes University, CHU Nantes, UMR 1280 PhAN, INRA, Nantes, France
| | | |
Collapse
|
23
|
Say M, Tella E, Boccara O, Sauvage M, Bourrat E, Tian Y, Monfort JB, Lok C, Desierier F, Beneton N, Abasq-Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour JP, Plantin P, Sigal ML, Mazereeuw-Hautier J, Mahé E. Leg ulcers in childhood: A multicenter study in France. Ann Dermatol Venereol 2021; 149:51-55. [PMID: 34218940 DOI: 10.1016/j.annder.2021.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 03/30/2021] [Accepted: 05/19/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Leg ulcers in adults are a major public health concern. Their incidence increases with age and many causes have been identified, predominantly associated with vascular diseases. Leg ulcers in children and teenagers are less frequent. The aim of our study was to identify the causes of leg ulcers in children and teenagers, and to evaluate their management. METHODS This retrospective multicenter study was conducted by members of the Angio-dermatology Group of the French Society of Dermatology and of the French Society of Pediatric Dermatology. Data from children and teenagers (< 18 years), seen between 2008 and 2020 in 12 French hospitals for chronic leg ulcer (disease course>4 weeks), were included. RESULTS We included 27 patients, aged from 2.3 to 17.0 years. The most frequent causes of leg ulcer were: general diseases (n=9: pyoderma gangrenosum, dermatomyositis, interferonopathy, sickle cell disease, prolidase deficiency, scleroderma, Ehlers-Danlos syndrome), vasculopathies (n=8: hemangioma, capillary malformation, arteriovenous malformation), trauma (n=4: bedsores, pressure ulcers under plaster cast), infectious diseases (n=4: pyoderma, tuberculosis, Buruli ulcer) and neuropathies (n=2). Comorbidities (59.3%) and chronic treatments (18.5%) identified as risk factors for delayed healing were frequent. The average time to healing was 9.1 months. DISCUSSION Leg ulcers are less frequent in children and teenagers than in adults and their causes differ from those in adults. Comorbidities associated with delayed healing must be identified and managed. Children and teenagers tend to heal faster than adults, but a multidisciplinary management approach is necessary.
Collapse
Affiliation(s)
- M Say
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France.
| | - E Tella
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - O Boccara
- Service de dermatologie, centre hospitalier universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - M Sauvage
- Service de dermatologie, centre de référence des Maladies Rares de la Peau, centre hospitalier universitaire Larrey, Université Paul-Sabatier, Toulouse, France
| | - E Bourrat
- Service de pédiatrie générale, centre hospitalier universitaire Robert-Debré, AP-HP, Paris, France
| | - Y Tian
- Service de pédiatrie générale, centre hospitalier universitaire Robert-Debré, AP-HP, Paris, France
| | - J-B Monfort
- Service de dermatologie, centre hospitalier universitaire Tenon, AP-HP, Paris, France
| | - C Lok
- Service de dermatologie, centre hospitalier universitaire Amiens-Picardie, Amiens, France
| | - F Desierier
- Service de dermatologie, centre hospitalier universitaire Amiens-Picardie, Amiens, France
| | - N Beneton
- Service de dermatologie, centre hospitalier du Mans, Le Mans, France
| | - C Abasq-Thomas
- Service de dermatologie, centre hospitalier Régional Universitaire de Brest, Brest, France
| | | | - S Mallet
- Service de dermatologie, centre hospitalier universitaire La Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J-P Lacour
- Service de dermatologie, centre hospitalier universitaire L'archet, Nice, France
| | - P Plantin
- Service de dermatologie, centre hospitalier de Cornouaille, Quimper, France
| | - M-L Sigal
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - J Mazereeuw-Hautier
- Service de dermatologie, centre de référence des Maladies Rares de la Peau, centre hospitalier universitaire Larrey, Université Paul-Sabatier, Toulouse, France
| | - E Mahé
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | | |
Collapse
|
24
|
Sorlin A, Carmignac V, Amiel J, Boccara O, Fraitag S, Maruani A, Theiler M, Weibel L, Duffourd Y, Philippe C, Thauvin-Robinet C, Faivre L, Rivière JB, Vabres P, Kuentz P. Expanding the clinical spectrum of mosaic BRAF skin phenotypes. J Eur Acad Dermatol Venereol 2021; 35:e690-e693. [PMID: 34051131 DOI: 10.1111/jdv.17413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 05/19/2021] [Indexed: 11/28/2022]
Affiliation(s)
- A Sorlin
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - V Carmignac
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - J Amiel
- Service de Génétique Médicale, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - O Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - S Fraitag
- Service d'Anatomie et de Cytologie Pathologiques, APHP, Hôpital Necker-Enfants Malades, Paris, France
| | - A Maruani
- Service de Dermatologie, Centre de Référence des Maladies Rares - MAGEC, Centre Hospitalier Universitaire de Tours, Université de Tours, SPHERE-INSERM 1246, Tours, France
| | - M Theiler
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - L Weibel
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - Y Duffourd
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - C Philippe
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - L Faivre
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - J-B Rivière
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - P Vabres
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Service de Dermatologie, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - P Kuentz
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France
| |
Collapse
|
25
|
Garde A, Guibaud L, Goldenberg A, Petit F, Dard R, Roume J, Mazereeuw-Hautier J, Chassaing N, Lacombe D, Morice-Picard F, Toutain A, Arpin S, Boccara O, Touraine R, Blanchet P, Coubes C, Willems M, Pinson L, Van Kien PK, Chiaverini C, Giuliano F, Alessandri JL, Mathieu-Dramard M, Morin G, Bursztejn AC, Mignot C, Doummar D, Di Rocco F, Cornaton J, Nicolas C, Gautier E, Luu M, Bardou M, Sorlin A, Philippe C, Edery P, Rossi M, Carmignac V, Thauvin-Robinet C, Vabres P, Faivre L. Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials. Clin Genet 2021; 99:650-661. [PMID: 33415748 DOI: 10.1111/cge.13918] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/17/2020] [Accepted: 01/04/2021] [Indexed: 11/30/2022]
Abstract
Megalencephaly-CApillary malformation-Polymicrogyria (MCAP) syndrome results from somatic mosaic gain-of-function variants in PIK3CA. Main features are macrocephaly, somatic overgrowth, cutaneous vascular malformations, connective tissue dysplasia, neurodevelopmental delay, and brain anomalies. The objectives of this study were to describe the clinical and radiological features of MCAP, to suggest relevant clinical endpoints applicable in future trials of targeted drug therapy. Based on a French collaboration, we collected clinical features of 33 patients (21 females, 12 males, median age of 9.9 years) with MCAP carrying mosaic PIK3CA pathogenic variants. MRI images were reviewed for 21 patients. The main clinical features reported were macrocephaly at birth (20/31), postnatal macrocephaly (31/32), body/facial asymmetry (21/33), cutaneous capillary malformations (naevus flammeus 28/33, cutis marmorata 17/33). Intellectual disability was present in 15 patients. Among the MRI images reviewed, the neuroimaging findings were megalencephaly (20/21), thickening of corpus callosum (16/21), Chiari malformation (12/21), ventriculomegaly/hydrocephaly (10/21), cerebral asymmetry (6/21) and polymicrogyria (2/21). This study confirms the main known clinical features that defines MCAP syndrome. Taking into account the phenotypic heterogeneity in MCAP patients, in the context of emerging clinical trials, we suggest that patients should be evaluated based on the main neurocognitive expression on each patient.
Collapse
Affiliation(s)
- Aurore Garde
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France
| | - Laurent Guibaud
- Service de Radiologie, Hôpital Femme-Mère-Enfant, Lyon, France
| | | | - Florence Petit
- Service de Génétique Clinique, Centre de Référence Anomalies du Développement CHU, Lille, France
| | - Rodolphe Dard
- Département de Génétique, CHI Poissy, St Germain-en-Laye, France
| | - Joelle Roume
- Département de Génétique, CHI Poissy, St Germain-en-Laye, France
| | - Juliette Mazereeuw-Hautier
- Département de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CHU de Toulouse, Toulouse, France
| | - Nicolas Chassaing
- Service de Génétique Médicale, INSERM U543, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Didier Lacombe
- INSERM U1211, Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France
| | - Fanny Morice-Picard
- INSERM U1211, Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France
| | | | | | - Olivia Boccara
- Département de Dermatologie, Centre de Reference MAGEC, Hopital universitaire Necker-Enfants malades, Paris, France
| | - Renaud Touraine
- Service de Génétique Clinique, Chromosomique et Moléculaire, Centre de Référence des Anomalies du Développement, CHU, de Saint-Etienne, France
| | - Patricia Blanchet
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Christine Coubes
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Marjolaine Willems
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Lucile Pinson
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | | | | | | | | | | | - Gilles Morin
- Service de Génétique Clinique, CHU Amiens-Picardie, Amiens, France
| | | | - Cyril Mignot
- Département de Génétique and Centre de Référence Déficiences Intellectuelles de Causes Rares, AP-HP, Sorbonne Université, Paris, France
| | - Diane Doummar
- Service de Neurologie pédiatrique, Hôpital Armand Trousseau, AP-HP, Paris, France
| | - Frederico Di Rocco
- Service de neurochirurgie pédiatrique, Hôpital Femme-Mère-Enfant, Lyon, France
| | - Jenny Cornaton
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Claire Nicolas
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Elodie Gautier
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Maxime Luu
- INSERM CIC 1432, Université de Bourgogne, Dijon, France
| | - Marc Bardou
- INSERM CIC 1432, Université de Bourgogne, Dijon, France
| | - Arthur Sorlin
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Christophe Philippe
- Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Patrick Edery
- Département de Génétique, Hospices Civils de Lyon et GENDEV, INSERM U1028, Lyon, France
| | - Massimiliano Rossi
- Département de Génétique, Hospices Civils de Lyon et GENDEV, INSERM U1028, Lyon, France
| | - Virginie Carmignac
- UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| | - Christel Thauvin-Robinet
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Pierre Vabres
- UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| | - Laurence Faivre
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| |
Collapse
|
26
|
Boccara O, Eyries M, Pannier S, Ariche-Maman S, Hadj-Rabia S, Coulet F. Mosaïcisme du gène RASA1 chez un patient atteint de syndrome de Parkes-Weber. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Morel B, Leducq S, Samimi M, Caille A, Maruani A. Qualité de vie chez les enfants ayant une malformation capillaire de membre inférieur : données dynamiques sur 5 ans (cohorte nationale multicentrique CONAPE). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Say M, Tella E, Boccara O, Mazereeuw Hautier J, Sauvage M, Bourrat E, Tian Y, Montfort J, Lok C, Dessierier F, Beneton N, Abasaq Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour J, Plantin P, Sigal M, Mahé E. Ulcères de membres inférieurs chez les enfants et les adolescents : étude multicentrique française. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Boccara O, Eyries M, Pannier S, Ariche-Maman S, Hadj-Rabia S, Coulet F. Parkes-Weber syndrome related to RASA1 mosaic mutation. Clin Genet 2020; 99:330-331. [PMID: 33118152 DOI: 10.1111/cge.13860] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 09/16/2020] [Accepted: 10/04/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Paris University, Imagine Institute, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | - Mélanie Eyries
- Department of Genetics, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, APHP, Sorbonne Université, Paris, France
| | - Stéphanie Pannier
- Department of orthopedic surgery, Paris University, Imagine Institute, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | - Sonia Ariche-Maman
- Department of pediatric radiology, Paris University, Imagine Institute, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | - Smail Hadj-Rabia
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Paris University, Imagine Institute, Necker-Enfants Malades University Hospital, APHP5, Paris, France
| | - Florence Coulet
- Department of Genetics, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, APHP, Sorbonne Université, Paris, France
| |
Collapse
|
30
|
El Zein S, Boccara O, Soupre V, Vieira AF, Bodemer C, Coulomb A, Wassef M, Fraitag S. The histopathology of congenital haemangioma and its clinical correlations: a long-term follow-up study of 55 cases. Histopathology 2020; 77:275-283. [PMID: 32281140 DOI: 10.1111/his.14114] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 04/02/2020] [Accepted: 04/04/2020] [Indexed: 01/12/2023]
Abstract
AIMS Congenital haemangiomas (CHs) can be subdivided into different subtypes [rapidly involuting CHs (RICHs), non-involuting CHs (NICHs), and partially involuting CHs (PICHs)]. During the first few days of life, RICHs may be associated with transient but sometimes marked thrombocytopenia. We sought to assess the histological aspects and clinicopathological correlations of the three subtypes. METHODS AND RESULTS We assessed the histopathological features of 10 RICHs, 25 NICHs, and 20 PICHs, described the patients' long-term clinical outcomes, and assessed clinicopathological correlations. All CHs were located in the dermis and hypodermis, and comprised both capillary lobules (with three distinct histopathological patterns) and extralobular large vessels. Most of the extralobular vessels were abnormal veins and abnormal lymphatic vessels. We did not observe significant correlations between the CH subtype, the histopathological pattern, and the time of the histopathological assessment. Interestingly, unexpected intralobular expression of podoplanin was found in neonatal biopsies of five RICHs and PICHs. Four of these five patients had concomitant thrombocytopenia. The podoplanin staining intensity decreased over time as the thrombocytopenia resolved and the tumour shrank. CONCLUSION The histopathological features were similar in all three subtypes of CH, and were related to the time since disease onset; we consider that RICH, PICH and NICH form a single entity and differ only in their involuting potential. Along with the transient expression of intralobular podoplanin observed in some specimens from the newborn, the lobular architecture might lead to misdiagnosis of tufted haemangioma or kaposiform haemangioendothelioma.
Collapse
Affiliation(s)
- Sophie El Zein
- Department of Biopathology, Institut Curie, Paris Sciences et Lettres Research University, Paris, France
| | - Olivia Boccara
- Paediatric Dermatology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Véronique Soupre
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Plastic and Maxillofacial Surgery Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Andre F Vieira
- Department of Biopathology, Institut Curie, Paris Sciences et Lettres Research University, Paris, France
| | - Christine Bodemer
- Paediatric Dermatology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Aurore Coulomb
- Department of Pathology, Armand Trousseau Hospital, AP-HP, Paris, France.,Pierre et Marie Curie University, Paris, France
| | - Michel Wassef
- Department of Pathology, Lariboisière Hospital, Paris Diderot University, Université de Paris, Paris, France
| | - Sylvie Fraitag
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Pathology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
31
|
Welfringer-Morin A, Pinto G, Baujat G, Vial Y, Hadj-Rabia S, Bodemer C, Boccara O. Hypophosphatemic rickets: A rare complication of congenital melanocytic nevus syndrome. Pediatr Dermatol 2020; 37:541-544. [PMID: 32157705 DOI: 10.1111/pde.14139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We report the case of a child who presented with a giant melanocytic nevus with numerous satellite nevi at birth and developed hypophosphatemic rickets due to excessive secretion of the FGF23 hormone. A NRAS c.182A>G (Q61R) mutation was identified in the lesional skin. The functional outcome was favorable with medical treatment.
Collapse
Affiliation(s)
- Anne Welfringer-Morin
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, Université de Paris, Paris, France
| | - Graziella Pinto
- Department of Endocrinology and Diabetology, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, Université de Paris, Paris, France
| | - Geneviève Baujat
- Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, Université de Paris, Paris, France
| | - Yoann Vial
- Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Paris, France.,INSERM UMR S1131, Institut Universitaire d'Hématologie, Université de Paris, Paris, France
| | - Smail Hadj-Rabia
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, Université de Paris, Paris, France
| | - Christine Bodemer
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, Université de Paris, Paris, France
| | - Olivia Boccara
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), APHP, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, Université de Paris, Paris, France
| |
Collapse
|
32
|
Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw‐Hautier J, Maruani A. Modalities of use of oral propranolol in proliferative infantile haemangiomas: an international survey among practitioners. Br J Dermatol 2020; 183:573-575. [DOI: 10.1111/bjd.19047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- J. Robert
- CHRU Tours, Department of Dermatology Unit of Pediatric Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC) CHRU Tours 37044 Tours CEDEX 9 France
| | - E. Tavernier
- Universities of Tours and Nantes INSERM 1246 – SPHERE 37000 Tours France
- CHRU Tours Clinical Investigation Center – INSERM 1415 37044 Tours CEDEX 9 France
| | - O. Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) Université Paris Paris‐Centre, Institut Imagine Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - J. Mashiah
- Pediatric Dermatology Unit Dana Children's Hospital Department of Dermatology and Venereology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel
- Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel
| | | | - A. Maruani
- CHRU Tours, Department of Dermatology Unit of Pediatric Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC) CHRU Tours 37044 Tours CEDEX 9 France
- Universities of Tours and Nantes INSERM 1246 – SPHERE 37000 Tours France
| |
Collapse
|
33
|
Bekhouche B, Tourville A, Ravichandran Y, Tacine R, Abrami L, Dussiot M, Khau-Dancasius A, Boccara O, Khirat M, Mangeney M, Dingli F, Loew D, Boëda B, Jordan P, Molina TJ, Bellon N, Fraitag S, Hadj-Rabia S, Blanche S, Puel A, Etienne-Manneville S, van der Goot FG, Cherfils J, Hermine O, Casanova JL, Bodemer C, Smahi A, Delon J. A toxic palmitoylation of Cdc42 enhances NF-κB signaling and drives a severe autoinflammatory syndrome. J Allergy Clin Immunol 2020; 146:1201-1204.e8. [PMID: 32283203 DOI: 10.1016/j.jaci.2020.03.020] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2019] [Revised: 03/24/2020] [Accepted: 03/27/2020] [Indexed: 11/19/2022]
Affiliation(s)
- Bahia Bekhouche
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France
| | - Aurore Tourville
- Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France
| | - Yamini Ravichandran
- Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Sorbonne Université, Collège doctoral, F-75005 Paris, France
| | - Rachida Tacine
- Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France
| | - Laurence Abrami
- Global Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland
| | - Michael Dussiot
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France
| | - Andrea Khau-Dancasius
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France
| | - Olivia Boccara
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker- Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - Meriem Khirat
- Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France
| | - Marianne Mangeney
- Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France
| | - Florent Dingli
- Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France
| | - Damarys Loew
- Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France
| | - Batiste Boëda
- Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Pénélope Jordan
- Fédération de Génétique, Service de Génétique Moléculaire, Hôpital Necker-Enfants Malades, Paris, France
| | - Thierry Jo Molina
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France; Department of Pathology, Necker Enfants Malades, Université de Paris, Paris, France
| | - Nathalia Bellon
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker- Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - Sylvie Fraitag
- Department of Pathology, reference centre MAGEC, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Smail Hadj-Rabia
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker- Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - Stéphane Blanche
- Unité d'Immunologie Hématologie Rhumatologie Pédiatrique, Necker-Enfants Malades Hospital (AP-HP5), Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Anne Puel
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Descartes University, Imagine Institute, Paris, France
| | - Sandrine Etienne-Manneville
- Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | | | - Jacqueline Cherfils
- Laboratoire de Biologie et Pharmacologie Appliquée, CNRS and Ecole Normale Supérieure Paris-Saclay, Cachan, France
| | - Olivier Hermine
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France; Department of Hematology, Hôpital Necker AP-HP, Paris, France
| | - Jean-Laurent Casanova
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Descartes University, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, Howard Hughes Medical Institute, New York, NY; Department of Pediatric Immunology and Hematology, Necker-Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Christine Bodemer
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker- Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France.
| | - Asma Smahi
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France.
| | - Jérôme Delon
- Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France.
| |
Collapse
|
34
|
Bertrand V, Boccara O, Filhon B, Manca F, Lefèvre G, Groh M, Kahn JE. Episodic angioedema with eosinophilia (Gleich syndrome) in children: A clinical review. Pediatr Allergy Immunol 2020; 31:297-302. [PMID: 31725177 DOI: 10.1111/pai.13173] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Revised: 09/20/2019] [Accepted: 11/07/2019] [Indexed: 01/28/2023]
Abstract
BACKGROUND Episodic angioedema with eosinophilia (EAE, Gleich syndrome) is a rare disease, consisting of recurrent angioedema with hypereosinophilia and frequent increased serum immunoglobulin M levels. Less than 100 patients have been reported, mainly adults, sometimes with underlying lymphocytic variant of hypereosinophilic syndrome (HESL ). The aim of this study was to identify and describe pediatric cases. METHODS We performed a retrospective study of all pediatric cases of EAE referred within the French National Referral Center for Hypereosinophilic Syndrome (CEREO). Next, the PRISMA guidelines were applied in order to perform a systematic review (data sources: PubMed, Web of Science). RESULTS Among the two reported and 15 previously published cases of EAE occurring in children, the main clinical findings mimicked those of adults, including recurrent angioedema, hives, and weight gain. The median time between the first angioedema flare and the diagnosis of EAE was 5 years in published cases. Hypereosinophilia was constant, usually worsening with each attack, but seldom disappeared between flares. Total IgM serum levels were elevated in 16 patients. Four children had evidence of abnormal CD3- CD4+ T cells. First-line therapy relied on oral corticosteroids in all patients, and further lines (used in five patients) included interferon-α, methotrexate, and cyclosporin. Two children developed eosinophilic myocarditis during follow-up. CONCLUSION Pediatricians should be aware that EAE is a diagnosis to consider in children. T-cell immunophenotyping is warranted in this setting. Prognosis seems fair, yet eosinophil-related organ damage may occur in patients with persistent eosinophilia.
Collapse
Affiliation(s)
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris Descartes - Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Bruno Filhon
- Pediatric Unit, Le Havre Hospital, Le Havre, France
| | | | - Guillaume Lefèvre
- National Referral Center for Hypereosinophilic Syndromes (CEREO), Suresnes, France.,Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU de Lille, Université de Lille, Lille, France
| | - Matthieu Groh
- National Referral Center for Hypereosinophilic Syndromes (CEREO), Suresnes, France.,Service de Médecin Interne, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Suresnes, France
| | - Jean-Emmanuel Kahn
- National Referral Center for Hypereosinophilic Syndromes (CEREO), Suresnes, France.,Service de Médecine Interne, Hôpital Ambroise Paré, Université Versailles-Saint Quentin-en-Yvelines, Boulogne-Billancourt, France
| |
Collapse
|
35
|
Kinsler V, Boccara O, Fraitag S, Torrelo A, Vabres P, Diociauti A. 皮肤镶嵌综述. Br J Dermatol 2020. [DOI: 10.1111/bjd.18838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Kinsler V, Boccara O, Fraitag S, Torrelo A, Vabres P, Diociauti A. A review of cutaneous mosaicism. Br J Dermatol 2020. [DOI: 10.1111/bjd.18825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Bar C, Pedespan JM, Boccara O, Garcelon N, Levy R, Grévent D, Boddaert N, Nabbout R. Early magnetic resonance imaging to detect presymptomatic leptomeningeal angioma in children with suspected Sturge-Weber syndrome. Dev Med Child Neurol 2020; 62:227-233. [PMID: 31050360 DOI: 10.1111/dmcn.14253] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/13/2019] [Indexed: 10/26/2022]
Abstract
AIM We aimed to evaluate the contribution of early magnetic resonance imaging (MRI) for the presymptomatic diagnosis of Sturge-Weber syndrome (SWS) in infants with a facial port-wine birthmark (PWB). METHOD Asymptomatic infants with a facial PWB who performed a first MRI scan before 3 months and a second MRI scan after 9 months were included in this study. Leptomeningeal enhancement on T1-weighted imaging and four indirect signs of leptomeningeal angioma (choroid plexus enlargement, cerebral atrophy, signal inversion of the white matter with T2 hyposignal, and T1 hypersignal) were screened on the first MRI scan and correlated with clinical and/or radiological diagnosis of SWS. RESULTS Thirteen of 30 included patients had SWS with leptomeningeal angioma. Eleven had a leptomeningeal enhancement on the first MRI scan and 10 had associated indirect signs. The presence of a direct or at least one indirect sign of leptomeningeal angioma on the first MRI scan confirmed the diagnosis of SWS with a sensitivity of 100 per cent (95% confidence interval 75-100%) and a specificity of 94 per cent (71-100%). INTERPRETATION Early diagnosis of SWS is possible on contrast-enhanced MRI performed in asymptomatic infants with a facial PWB before the age of 3 months. This early detection would help to select patients who may benefit from early neuroprotective intervention. WHAT THIS PAPER ADDS Specific magnetic resonance imaging markers provide early diagnosis of leptomeningeal angioma in Sturge-Weber syndrome (SWS). Presymptomatic diagnosis of SWS should help to select patients for early therapy intervention.
Collapse
Affiliation(s)
- Claire Bar
- Department of Paediatric Neurology, Hôpital Necker-Enfants Malades, Reference Centre for Rare Epilepsies, APHP, Bordeaux, France.,Imagine Institute UMR 1163, Paris, France.,Department of Paediatric Neurology, Hôpital des Enfants, CHU Bordeaux, Bordeaux, France
| | - Jean-Michel Pedespan
- Department of Paediatric Neurology, Hôpital des Enfants, CHU Bordeaux, Bordeaux, France
| | - Olivia Boccara
- Department of Paediatric Dermatology, Hôpital Necker-Enfants Malades, Paris, France
| | - Nicolas Garcelon
- Imagine Institute UMR 1163, Paris, France.,Paris Descartes University, Sorbonne Paris Cite, Paris, France.,Centre de Recherche des Cordeliers, INSERM, UMR 1138 Equipe 22, Paris, France
| | - Raphael Levy
- Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France
| | - David Grévent
- Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France
| | - Nathalie Boddaert
- Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France
| | - Rima Nabbout
- Department of Paediatric Neurology, Hôpital Necker-Enfants Malades, Reference Centre for Rare Epilepsies, APHP, Bordeaux, France.,Imagine Institute UMR 1163, Paris, France.,Paris Descartes University, Sorbonne Paris Cite, Paris, France
| |
Collapse
|
38
|
Boccara O, Galmiche‐Rolland L, Dadone‐Montaudié B, Ariche‐Maman S, Coulet F, Eyries M, Pannier S, Soupre V, Molina T, Pedeutour F, Fraitag S. Soft tissue angiomatosis: another
PIK3CA
‐related disorder. Histopathology 2020; 76:540-549. [DOI: 10.1111/his.14021] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 10/17/2019] [Indexed: 12/26/2022]
Affiliation(s)
- Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) Université Paris, Paris‐centre Institut Imagine Hôpital Universitaire Necker‐Enfants Malades APHP ParisFrance
| | | | - Bérengère Dadone‐Montaudié
- Laboratory of Solid Tumour Genetics Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 Université Côte d'Azur Centre Hospitalier Universitaire de Nice Nice France
| | - Sonia Ariche‐Maman
- Department of Pediatric Radiology Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - Florence Coulet
- Genetics Groupe hospitalier Pitié‐Salpêtrière Université Pierre et Marie Curie APHP Paris France
| | - Mélanie Eyries
- Genetics Groupe hospitalier Pitié‐Salpêtrière Université Pierre et Marie Curie APHP Paris France
| | - Stéphanie Pannier
- Department of Orthopedic Surgery Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - Véronique Soupre
- Maxillofacial Surgery and Stomatology Department Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - Thierry Molina
- Department of Pathology Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - Florence Pedeutour
- Laboratory of Solid Tumour Genetics Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 Université Côte d'Azur Centre Hospitalier Universitaire de Nice Nice France
| | - Sylvie Fraitag
- Department of Pathology Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| |
Collapse
|
39
|
Leducq S, Caille A, Barbarot S, Bénéton N, Bessis D, Boccara O, Bursztejn AC, Chiaverini C, Dompmartin A, Droitcourt C, Gissot V, Goga D, Guibaud L, Herbreteau D, Le Touze A, Léauté-Labrèze C, Lorette G, Mallet S, Martin L, Mazereeuw-Hautier J, Phan A, Plantin P, Quéré I, Vabres P, Bourgoin H, Giraudeau B, Maruani A. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials 2019; 20:739. [PMID: 31847908 PMCID: PMC6918625 DOI: 10.1186/s13063-019-3767-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Accepted: 09/29/2019] [Indexed: 12/12/2022] Open
Abstract
Background Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and impaired quality of life. The treatment is challenging. Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) involved in angio-lymphangiogenesis. Topical sirolimus has recently been reported as effective in a few reports of patients with CMLMs. The objective is to compare the efficacy and safety of a 12-week application of 0.1% topical sirolimus versus topical vehicle in CMLMs in children and adults. Methods This French blinded multicenter within-person randomized controlled phase 2 trial aims to include 55 patients aged ≥ 6 years who have a primary CMLM. The CMLM will be divided into two equal areas that will be randomly allocated to 0.1% topical sirolimus or topical vehicle applied for 12 weeks. At the end of the 12-week period, the patient/parent will treat the whole area of CMLM with 0.1% topical sirolimus on remaining lesions, for eight more weeks. Patients will be seen at week 20 (treatment will be stopped) and at month 12 to evaluate long-term efficacy. The primary outcome will be improvement of the CMLM in the area treated with topical sirolimus compared to the area treated with topical vehicle by the investigator physician (blinded to the treatment) with the Physician Global Assessment score at week 12. Secondary outcomes will include: assessment of efficacy by independent experts on the basis of standardized photographs; impact on quality of life; efficacy for oozing, bleeding, erythema, and thickness evaluated by the investigators; and global efficacy as well as efficacy for functional and aesthetic impairment evaluated by the patient. Systemic passage of sirolimus will be measured at weeks 6, 12, and 20, and at week 16 for CMLMs ≥ 900 cm2. Discussion For patients with CMLMs, topical sirolimus could be a non-invasive and well-tolerated therapeutic option. If the trial demonstrates efficacy and safety of this treatment, this result will lead to a real change in the management of this condition, and 0.1% sirolimus cream would become the first-line treatment. Trial registration ClinicalTrials.gov, NCT03972592. Registered on 3 June 2019. EU Clinical Trials Register EudraCT, 2018–001359-11.
Collapse
Affiliation(s)
- Sophie Leducq
- INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France. .,Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France. .,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.
| | - Agnès Caille
- INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France.,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France
| | - Sébastien Barbarot
- Department of Dermatology, University Hospital Center of Nantes, 44000, Nantes, France
| | - Nathalie Bénéton
- Department of Dermatology, Hospital Center of le Mans, 72037, le Mans, France
| | - Didier Bessis
- Department of Dermatology, University Hospital Center of Montpellier, 34000, Montpellier, France
| | - Olivia Boccara
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), University Hospital Necker-Enfants Malades, 75015, Paris, France
| | - Anne-Claire Bursztejn
- Department of Dermatology, University Hospital Center of Nancy, 54000, Nancy, France
| | - Christine Chiaverini
- Department of Dermatology, University Hospital Center of Nice, 06000, Nice, France
| | - Anne Dompmartin
- Department of Dermatology, University Hospital Center of Caen, 54000, Caen, France
| | - Catherine Droitcourt
- Department of Dermatology, University Hospital Center of Rennes, 35000, Rennes, France
| | - Valérie Gissot
- Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France
| | - Dominique Goga
- Department of Maxillo-Facial surgery, CHRU Tours, 37044, Tours, Cedex 9, France
| | - Laurent Guibaud
- University Hospital Center of Lyon, Consultation Multidisciplinaire Lyonnaise des Angiomes, 69229, Lyon, Cedex 2, France
| | | | - Anne Le Touze
- Department of Pediatric Surgery, CHRU Tours, 37000, Tours, France
| | | | - Gérard Lorette
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France
| | - Stéphanie Mallet
- Department of Dermatology, University Hospital Center of Marseille, 13885, Marseille, Cedex 5, France
| | - Ludovic Martin
- Department of Dermatology, University Hospital Center of Angers, 49000, Angers, France
| | - Juliette Mazereeuw-Hautier
- Reference center for rare skin diseases, Department of Dermatology, University Hospital Center of Toulouse, Paul Sabatier University, 31059, Toulouse, France
| | - Alice Phan
- Department of Dermatology, University Hospital Center of Lyon, 69229, Lyon, Cedex 2, France
| | - Patrice Plantin
- Department of Dermatology, Hospital Center of Quimper, 29107, Quimper, France
| | - Isabelle Quéré
- Departement of Vascular Medicine, National Reference Centre for Rare Vascular Diseases, EA 2992 Research Team, University of Montpellier, University Hospital Center of Montpellier, 34000, Montpellier, France
| | - Pierre Vabres
- Department of Dermatology, University Hospital Center of Dijon, 21000, Dijon, France
| | - Hélène Bourgoin
- Department of Pharmacy, University Hospital Center of Tours, 37000, Tours, France
| | - Bruno Giraudeau
- INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France.,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France
| | - Annabel Maruani
- INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France. .,Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France. .,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.
| | | |
Collapse
|
40
|
Boccara O, Soupre V, Brunelle F, Ariche-Maman S, Dabudyk T, Proust S, Hadj-Rabia S, Bodemer C. Phénomène de Kasabach-Merrit traité par sirolimus : évolution à long terme ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D’Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Hervé G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guérin F, Sepulveda F, Bagot M, De Saint-Basile G, Michonneau D, De Masson A. Étude clinique à long terme et mutations HAVCR2 chez 70 patients atteints de lymphome T sous cutané à type de panniculite. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
42
|
Carmignac V, El Zein S, Boccara O, Chevarin M, Duffourd Y, Bodemer C, Martin L, Fraitag S, Vabres P. Profil génétique des tumeurs cutanées vasculaires congénitales du nourrisson. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw-Hautier J, Maruani A. Modalités d’utilisation du propranolol dans les hémangiomes infantiles : un questionnaire international auprès des praticiens. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Collignon C, Carton M, Brisse HJ, Pannier S, Gauthier A, Sarnacki S, Tiléa B, Savignoni A, Helfre S, Philippe-Chomette P, Cardoen L, Boccara O, Pierron G, Orbach D. Soft tissue sarcoma in children, adolescents and young adults: Outcomes according to compliance with international initial care guidelines. Eur J Surg Oncol 2019; 46:1277-1286. [PMID: 31839437 DOI: 10.1016/j.ejso.2019.11.518] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 11/14/2019] [Accepted: 11/29/2019] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Outcomes for adults with soft tissue sarcoma are better when managed at referral centers. Care guidelines advise for 5 main criteria: 1-Imaging before biopsy; 2-Tumor biopsy before surgery; 3-Multidiscipinary team discussion (MTD) before biopsy; 4-Biopsy in "expert centers"; 5-Somatic molecular biology feasible. The aim is to describe and assess the prognostic impact of initial management of STS according to the type of referring centers and the number of optimal criteria. METHODS Monocentric retrospective analysis of the management of 127 youths (0-25 years) with localized STS treated from 2006 to 2015. RESULTS Median age at diagnosis was 9.6 years (range: 025). Overall, only 41% patients had 5/5, 28% 3-4, 31% ≤2. No adequate imaging was performed before surgery/biopsy for 18% patients, no biopsy before treatment for 29%. Patients referred by "expert centers" had higher compliance to guidelines (P = 0.025). Upfront surgery was performed in 59/127 patients. Immediate re-operation was inversely related to the number of criteria (0% when 5 criteria vs. 14% for 3-4, 46% if ≤ 2; P < 0.001). For malignant tumors, outcome was better when 5 criteria were reached: 5 year EFS 90.8% (81.4-100.0%) vs. 71.6 for (60.4-84.9%; ≤4 criteria; p = 0.033), OS 93.6% (85.5-100%) vs. 79.5% (68.9-91.8%; p = 0.11), and LRFFS 90.6% (81.0-100.0) vs. 73.1% (62.0-86.3%; p = 0.047). CONCLUSION Less than half of the youths with STS are initially managed according to international guidelines, highlighting the need for better information about optimal management. These results plead for immediate management in reference centers to reduce initial burden of therapy.
Collapse
Affiliation(s)
- C Collignon
- SIREDO Oncology Center Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer Institut Curie, PSL University, Paris, France.
| | - M Carton
- Department of Biostatistics, Institut Curie, PSL University, Paris, France
| | - H J Brisse
- Imaging Department, Institut Curie, Paris, France
| | - S Pannier
- Department of Orthopedic Pediatric Surgery, Necker Enfants Malades Hospital, Paris, France; Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - A Gauthier
- Department of Pathology, Institut Curie, Paris, France
| | - S Sarnacki
- Department of Pediatric Surgery and Urology, Necker Enfants Malades Hospital, Paris, France; Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - B Tiléa
- Department of Radiology, Robert Debré́ Hospital, Paris, France
| | - A Savignoni
- Department of Biostatistics, Institut Curie, PSL University, Paris, France
| | - S Helfre
- Department of Radiotherapy, Institut Curie, Paris, France
| | | | - L Cardoen
- Imaging Department, Institut Curie, Paris, France
| | - O Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, France
| | - G Pierron
- Department of Somatic Genetics, Institut Curie, Paris, France
| | - D Orbach
- SIREDO Oncology Center Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer Institut Curie, PSL University, Paris, France
| |
Collapse
|
45
|
Gabeff R, Boccara O, Soupre V, Lorette G, Bodemer C, Herbreteau D, Tavernier E, Maruani A. Efficacy and Tolerance of Sirolimus (Rapamycin) for Extracranial Arteriovenous Malformations in Children and Adults. Acta Derm Venereol 2019; 99:1105-1109. [PMID: 31386166 DOI: 10.2340/00015555-3273] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Managing extracranial arteriovenous malformations is challenging. Sirolimus (rapamycin) is increasingly being used when surgery and embolization are not advised. Because of its anti-angiogenic properties here we report all extracranial arteriovenous malformation cases treated with sirolimus in 2 French tertiary centers for vascular anomalies. The outcomes were efficacy (complete, partial, no response) based on arteriovenous malformation volume and necrosis/hemorrhage and side effects. We retrospectively included 10 patients (7 children). The sirolimus dose ranged from 0.6 to 3.5 mg/m2. Median (interquartile range [IQR]) treatment time was 24.5 (4.5; 35) months. Five patients showed no response and 5 showed partial response at a median (IQR) of 3 (1; 5) months followed in 2 cases by therapeutic resistance (i.e., progressive disease after 9 and 24 months of treatment). The most frequent side effect was mouth ulcers. This study shows poor efficacy of sirolimus for treating extracranial arteriovenous malformations.
Collapse
Affiliation(s)
- Romain Gabeff
- University of Tours, CHRU Tours, FR-37044 Tours, France
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Giraud L, Welfringer-Morin A, Boccara O, Frassati-Biaggi A, Leclerc-Mercier S, Grootenboer-Mignot S, Bodemer C, Hadj-Rabia S. Neonatal and self-healing linear immunoglobulin A dermatosis. J Eur Acad Dermatol Venereol 2019; 34:e86-e87. [PMID: 31574167 DOI: 10.1111/jdv.15989] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L Giraud
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - A Welfringer-Morin
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - O Boccara
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - A Frassati-Biaggi
- Department of Pathology, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - S Leclerc-Mercier
- Department of Pathology, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - S Grootenboer-Mignot
- Department of Immunology, APHP, Bichat Hospital, Inserm UMR 1152, Université Paris Diderot Paris 7, Paris, France
| | - C Bodemer
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - S Hadj-Rabia
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| |
Collapse
|
47
|
Kinsler VA, Boccara O, Fraitag S, Torrelo A, Vabres P, Diociaiuti A. Mosaic abnormalities of the skin: review and guidelines from the European Reference Network for rare skin diseases. Br J Dermatol 2019; 182:552-563. [PMID: 30920652 DOI: 10.1111/bjd.17924] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/19/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Cutaneous mosaicism is an area of dermatology in which there has been an explosion of knowledge within the current decade. This has led to fundamental changes in the understanding of the conditions in this field, and to an ongoing paradigm shift in the approach to management of mosaic skin disorders. OBJECTIVES To lay out the general principles of mosaicism as they are currently understood, summarize the known cutaneous mosaic abnormalities of the skin with associated phenotypic and genotypic information, review the latest trials on targeted therapies and propose guidelines for the general approach to a patient with suspected mosaicism. METHODS This was a consensus expert review as part of the European Reference Network project (ERN-Skin). CONCLUSIONS This study provides clinicians with a practical approach to the patient with suspected mosaicism, redefines mosaicism for the modern genetic era, and proposes a new classification system based on genetic mechanism. What's already known about this topic? Cutaneous mosaicism is a complex field of dermatology that encompasses most birthmarks, and many rare syndromes. Some cutaneous patterns are known to be seen in mosaicism. Very few treatment options are available for most mosaic abnormalities of the skin. Recent high-sensitivity genetic techniques have led to an explosion of knowledge about genotype and phenotype in the literature. What does this study add? Expert consensus from the European Reference Network project. Review of knowledge of confirmed mosaic abnormalities of the skin, including cutaneous phenotype, extracutaneous associated features and genotype. Proposed new classification of mosaic abnormalities of the skin by genetic mechanism and therefore inheritance potential. Practical tips on correct sample collection and genetic investigation. Review of trials of targeted therapies. Guidelines for a practical clinical approach to the patient with suspected mosaicism.
Collapse
Affiliation(s)
- V A Kinsler
- Paediatric Dermatology, Great Ormond Street Hospital for Children, London, U.K.,Genetics and Genomic Medicine, UCL Institute of Child Health, London, U.K
| | - O Boccara
- Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris Descartes - Sorbonne Paris Cité, Institut Imagine, Paris, France
| | - S Fraitag
- Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - A Torrelo
- Department of Dermatology, Hospital Infantil del Niño Jesús, Madrid, Spain
| | - P Vabres
- Department of Dermatology and Reference Centre for Rare Skin Diseases, Dijon University Hospital, Dijon, France.,GAD, Genetics of Anomalies of Development, University of Bourgogne, Dijon, France
| | - A Diociaiuti
- Dermatology Unit, Bambino Gesù Children's Hospital, Rome, Italy
| |
Collapse
|
48
|
Schreiber A, Soupre V, Kadlub N, Galliani E, Picard A, Chrétien-Marquet B, Pannier S, Guéro S, Khen-Dunlop N, Hadj-Rabia S, Delanoe P, Bodemer C, Boccara O. Does surgery of lymphatic malformations lead to an increase in superficial lymphangiectasia? A retrospective study of 43 patients. Br J Dermatol 2019; 181:1324-1325. [PMID: 31222726 DOI: 10.1111/bjd.18236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A Schreiber
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - V Soupre
- Department of Plastic and Maxillo-Facial Surgery, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - N Kadlub
- Department of Plastic and Maxillo-Facial Surgery, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - E Galliani
- Department of Plastic and Maxillo-Facial Surgery, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - A Picard
- Department of Plastic and Maxillo-Facial Surgery, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - B Chrétien-Marquet
- Department of Plastic and Maxillo-Facial Surgery, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - S Pannier
- Department of Orthopaedic Surgery, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - S Guéro
- Department of Orthopaedic Surgery, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - N Khen-Dunlop
- Department of Paediatric Surgery, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - S Hadj-Rabia
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - P Delanoe
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - C Bodemer
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - O Boccara
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015, Paris, France, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| |
Collapse
|
49
|
Dequidt L, Franck N, Sanchez‐Pena P, Dalle S, Adamski H, Boulinguez S, Ingen‐Housz‐Oro S, Ram‐Wolff C, Boccara O, Bonnet N, Cortes B, Gouraud A, Grange F, Le Corre Y, Quereux G, De Masson A, Schmutz J, Skowron F, Verneuil L, Beylot‐Barry M. Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. Br J Dermatol 2019; 181:616-618. [DOI: 10.1111/bjd.17834] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L. Dequidt
- Dermatology Department University Hospital Bordeaux France
- INSERM U1053 Bordeaux Research in Translational Oncology Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux France
| | - N. Franck
- Dermatology Department AP‐HP Cochin Hospital Paris France
| | - P. Sanchez‐Pena
- Pharmacovigilance Centre Medical Pharmacology Department University Hospital Bordeaux France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - M. Beylot‐Barry
- Dermatology Department University Hospital Bordeaux France
- INSERM U1053 Bordeaux Research in Translational Oncology Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux France
| |
Collapse
|
50
|
Hardy J, Boralevi F, Mallet S, Cabrera N, Belot A, Phan A, Barbarot S, Duriez-Lasek A, Chiaverini C, Hubiche T, Mahé E, Bégon E, Bourrat E, Boccara O, Aubert H, Lerosey MG, Droitcourt C, Piram M, Mazereeuw-Hautier J. Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma. Acta Derm Venereol 2019; 99:539-543. [PMID: 30810215 DOI: 10.2340/00015555-3155] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho-trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho-trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho-trexate and we did not identify a clinical profile for those resistant patients.
Collapse
Affiliation(s)
- Juliette Hardy
- Reference Centre of Rare Skin Diseases, Larrey Hospital, Paul Sabatier University, 31400 Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|